Form 8-K Filing Summary

Catalyst Pharmaceuticals, Inc. has reported a delay in a bench trial concerning the validity of their Orange Book-listed patents for FIRDAPSE®. The trial, originally scheduled for March 23, 2026, has been postponed by the District Court for the District of New Jersey to May 18, 2026. The patents in question are related to FIRDAPSE® and are set to expire in 2032, 2034, and 2037. This delay impacts the legal proceedings surrounding the company's key product.